Expert Perspectives on Nonsteroidal MRAs and Cardiorenal Protection
Muthiah Vaduganathan, MD, MPH
Anuradha Lala-Trindade, MD
Brendon Neuen, MBBS, PhD
Impact of Finerenone on eGFR Slope by Baseline Albuminuria in FINEARTS-HF
Finnian R. McCausland, MD
Topline Results of the CONFIDENCE Trial
Rajiv Agarwal, MBBS, MD, FASN, BRCU
Practical Strategies for Optimizing Outcomes in Patients with Iron Deficiency and Heart Failure
Robert J. Mentz, MD, FHFSA, FACC, FAHA
Piotr Ponikowski, MD, PhD, FESC, FHFA
Shifting Treatment Paradigm in HFmrEF/HFpEF: Steroidal and Nonsteroidal MRAs
Faiez Zannad, MD, PhD
John McMurray, MD
Remnant Cholesterol: The Missing Link in ASCVD risk
Børge G. Nordestgaard, MD, DMSc
Kausik Ray, MBChB, MD, MPhil
The Road Ahead: What's on the Horizon for FCS and SHTG Management
Pam R. Taub, MD, FACC, FASPC
Prof. Kausik Ray
Targeting Mixed Hyperlipidemia with APOC3 Inhibition
Novel Therapies in Managing Patients With Cardiovascular-Kidney-Metabolic Syndrome and Heart Failure
Riccardo Maria Inciardi, MD, PhD
Cristina Gavina, MD, PhD
Giuseppe Galati, MD
FINE-HEART Pooled Analysis
Maria Pabon
Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial
John Ostrominski
Analysis of Patients With and Without AF Living With HFmrEF/HFpEF: FINEARTS-HF
Akshay S. Desai, MD
NYHA FC and Finerenone Response: Clinical Trial Insights
Mode of Death in Patients With HFmrEF/HFpEF: The FINEARTS-HF Trial
Echo essentials for HCM: The heartbeat of diagnosis and treatment
Thor Edvardsen, MD, PhD
Maurizio Pieroni, MD, PhD
Elena Arbelo, MD, PhD
Echocardiographic workup for HCM – making the diagnosis and evaluation of cardiac function
Loading...
We're glad to see you're enjoying PACE-CME… but how about a more personalized experience?
Press cancel to remain on PACE-CME. Press the link below or the continue button to keep going.